This article is sponsored by ADM
In this exclusive video interview, Nutraceutical Business Review talks to ADM’s Global Scientific Marketing Director for Health and Wellness, Aouatef Bellamine about the rise of GLP-1 medication use globally.
She also explores the impact that these drugs are having on the consumer market, and what opportunities they can bring to both the nutraceutical and functional food markets.
With a huge uptick in prescriptions for these type II diabetes and obesity-fighting drugs, Aouatef and the team at ADM believe that both nutraceutical and supplement companies would benefit from catering to this patient population — whether that be through the mitigation of side effects or by nourishing the body in periods of significant weight loss.
For more interviews with leading companies from across the nutraceutical industry, visit our YouTube channel and hit subscribe.
Nutraceutical Business Review in conversation with...
'Nutraceutical Business Review in conversation with' is a series of exclusive video interviews with leading companies in the nutraceutical industry, conducted by our team of B2B journalists.
For more information on how you can be part of 'Nutraceutical Business Review in conversation with' contact Chris Clark on 07442 736 880, or via email at chris@hpcimedia.com.
This interview was led by Annabel Kartal-Allen from Nutraceutical Business Review.